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PURPOSE. The majority of anterior corneal dystrophies are caused by dominant mutations in
TGFBI (transforming growth factor b-induced) collectively known as the epithelial-stromal
TGFBI dystrophies. Most cases of epithelial basement membrane dystrophy (EBMD) are
thought to result from a degenerative (nongenetic) process; however, a minority of cases are
associated with specific TGFBI mutations. We evaluated the spectrum of TGFBI mutations
and associated phenotypes in a United Kingdom cohort with typical epithelial-stromal TGFBI
dystrophies and an EBMD cohort.
METHODS. We recruited 68 probands with a clinical diagnosis of epithelial-stromal TGFBI
dystrophy and 23 probands with bilateral EBMD. DNA was extracted from peripheral
leukocytes, and TGFBI was bi-directly Sanger sequenced.
RESULTS. Nine TGFBI mutations were identified. The most common occurred at the mutation
hot-spot residues R124 and R555 in 61 probands; these individuals had a genotype–
phenotype correlation consistent with prior reports. Four probands with lattice corneal
dystrophy carried a mutation in exon 14: p.(A620D), p.(V625D), and p.(H626R). We
identified a p.(G623D) mutation in five probands, including two probands from the EBMD
cohort. These subjects typically had an onset of severe recurrent corneal epithelial erosion in
the fourth decade with mild diffuse or geographic subepithelial corneal opacities and only
small anterior stromal lattice structures in older individuals. Symptoms of painful epithelial
erosion improved markedly following phototherapeutic keratectomy.
CONCLUSIONS. There was a strong correlation between genotype and phenotype for the
majority of TGFBI mutations. In this cohort, the p.(G623D) mutation caused a greater
proportion of TGFBI-associated disease than anticipated, associated with variable phenotypes
including individuals diagnosed with EBMD.
Keywords: TFGBI, corneal dystrophy, granular, lattice, Reis-Bu¨cklers, Thiel-Behnke, epithelial
basement membrane dystrophy
Corneal dystrophies are a group of clinically and geneticallyheterogeneous disorders that cause corneal opacity with
impaired vision and painful recurrent erosions. Dominant
mutations in TGFBI (transforming growth factor b-induced)
cause a number of clinically distinct corneal dystrophies
including Reis-Bu¨cklers corneal dystrophy (RBCD), Thiel-
Behnke corneal dystrophy (TBCD), lattice corneal dystrophy
(LCD), and granular corneal dystrophy (GCD). These mutations
lead to an accumulation of TGFBI in the epithelial and stromal
layers of the cornea. TGFBI mutations affecting amino acid
residues R124 and R555 are the most common and are typically
associated with a characteristic phenotype across ethnically
diverse populations.1,2
Reis-Bu¨cklers corneal dystrophy and TBCD are anterior
stromal dystrophies caused by the TGFBI mutations p.(R124L)
and p.(R555Q), respectively.1,3 Clinically, RBCD is associated
with a geographic pattern of superficial corneal opacities,
whereas TBCD has a honeycomb pattern; although it is not
always possible to use this difference to reliably distinguish
between the two conditions. These dystrophies are character-
ized by a deposition of continuous protein fibers primarily in
the subepithelium and Bowman’s layer. Histologically, they can
be distinguished using Masson’s trichrome by positive staining
of RBCD deposits, which is absent in TBCD. Deposits of
straight, rod-like collagen fibers are observed in RBCD corneal
tissue by electron microscopy, whereas TBCD is associated
with curly fibers.4,5
Lattice corneal dystrophy is characterized by the deposition
of amyloid, primarily in the stroma, that produces a clinical
appearance of thin, branching refractile lattice lines. Histology
reveals fusiform deposits scattered throughout the stroma,
concentrated predominantly below Bowman’s layer.5 A range of
LCD phenotypes have been described, which vary in the
appearance of the lattice lines, the severity of diffuse stromal
haze, and the age of onset. The classic LCD phenotype is
associated with the TGFBI mutation p.(R124C), whereas a
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number of mutations, located predominantly in exon 14, are
responsible for the many phenotypic variants of LCD.6
Granular corneal dystrophy type 1 (GCD1) is characterized
by granular ‘‘crumb-like’’ deep stromal opacities, whereas
individuals with GCD type 2 (GCD2) predominantly have a
superficial ‘‘snowflake’’ pattern of opacities.2 In GCD1, histol-
ogy demonstrates distinct hyaline deposits in the corneal stroma
that stain positively with eosin and Masson’s trichrome, whereas
GCD2 is also positive for the presence of amyloid.5 Granular
corneal dystrophy type 1 is caused by TGFBI mutation
p.(R555W) or p.(R124S), whereas GCD2 is caused by the
mutation p.(R124H).1 This striking genotype–phenotype corre-
lation for epithelial-stromal TGFBI dystrophies suggests that
each mutation has a specific gain-of-function effect.
Individuals with epithelial basement membrane dystrophy
(EBMD) have thickening and reduplication of the epithelial
basement membrane that appear clinically as map, dot,
fingerprint, or bleb-like changes.7 These can also be associated
with painful recurrent corneal erosions.8 Epithelial basement
membrane dystrophy is considered to be a degenerative
(nongenetic) disorder in the majority of individuals9; however,
two dominant TGFBI mutations (p.[L509R] and p.[R666S])
have been reported in 3 probands with EBMD.10 Recently,
COL17A1 mutations have been identified as the cause of
epithelial recurrent erosion dystrophy (ERED), although the
cornea can initially appear normal in these individuals
between erosion episodes, without stromal deposits.11 There-
fore, the clinical condition of recurrent corneal erosion is
likely genetically heterogeneous, or degenerative in some in-
stances.
Resequencing studies in a wide range of populations have,
to date, identified over 60 TGFBI mutations that cause corneal
dystrophy. In this study, we investigated the spectrum of
TGFBI mutations present in a large multi-ethnic UK cohort
with epithelial-stromal TGFBI dystrophies. We also screened
TGFBI in an additional cohort of patients with a diagnosis of
bilateral EBMD. We have correlated these genetic findings with
the presenting clinical phenotype and identified a novel
association of EBMD with the TGFBI p.(G623D) mutation.
MATERIALS AND METHODS
Patient Recruitment and Clinical Examination
This study adhered to the tenets of the Declaration of Helsinki
and had research ethics committee approval (REC: 13/LO/
1084). Patients and relatives, where available, with a clinical
diagnosis of RBCD, TBCD, LCD, GCD, or EBMD were examined
at Moorfields Eye Hospital by a clinician experienced in
inherited and acquired corneal disease (SJT). Data collected
included family history, medical history, age of onset, and
previous ocular surgery (e.g., keratoplasty, phototherapeutic
keratectomy). Affected individuals had photographic docu-
mentation of their corneal changes. Patients with EBMD were
included if they were bilaterally affected with subepithelial
lines, cysts, or geographic opacities without a history of prior
traumatic corneal abrasion. For patients who had keratoplas-
ties, histology was performed for confirmation of affected
disease status.
Histology
Corneal tissue submitted for examination following keratoplas-
ty was processed and stained with hematoxylin and eosin
(H&E), periodic acid Schiff (PAS), Masson’s trichrome, and
Congo red by routine methods,12 and then examined by light
microscopy.
Genetic Screening
DNA was extracted from peripheral blood leukocytes using
standard methods. TGFBI exons previously identified to harbor
mutations (exons 4, 11, 12, 13, 14, and 16) were initially
amplified by PCR (Supplementary Table S1) and Sanger
sequenced in all probands, using standard protocols. Individ-
uals who were negative for mutations within these exons were
subsequently Sanger sequenced for all remaining TGFBI coding
exons (17 coding exons in total). Individuals in the EBMD
cohort who were negative for mutations in TGFBI were
subsequently screened for two known mutations in COL17A1
that have been associated with ERED. Sequences were aligned
and compared with the reference sequence using DNASTAR
Lasergene package software (Version 8.0.2; DNASTAR, Inc.,
Madison, WI, USA). Variants were annotated according to the
NM_000358.2 transcript with þ1 representing the start of
translation. Minor allele frequency (MAF) was determined
using the exome aggregation consortium (ExAC) database
(available in the public domain at http://exac.broadinstitute.
org/).13 Pathogenicity prediction programs SIFT (available in
the public domain at http://sift.jcvi.org/)14 and Polyphen2
(available in the public domain at http://genetics.bwh.harvard.
edu/pph2/)15 were used to predict the likely pathogenicity of
variants. Segregation of variants was undertaken if DNA
samples were available from additional family members.
RESULTS
Patient Cohort
A total of 91 probands (F1–F91) were recruited to the study,
with a total of 110 DNA samples obtained for extended
pedigrees. Sixty-eight probands had a clinical diagnosis of an
epithelial-stromal TGFBI-associated dystrophy (RBCD, TBCD,
LCD, and GCD). The majority of these probands had a family
history of corneal disease that was consistent with an
autosomal dominant pattern of inheritance. The remaining
23 probands were diagnosed with bilateral EBMD. Three EBMD
probands had a positive family history of the corneal disease,
with symptoms in at least one first-degree relative (F70, F88,
and F90).
All TGFBI mutations identified were predicted to be
pathogenic by SIFT and Polyphen2, except p.(R555Q), and
have been previously identified as causing an epithelial-stromal
TGFBI dystrophy. The majority were absent from the ExAC
database with the exception of p.(R124C), present at a
frequency of 0.0000083, and p.(R124H), present at a
frequency of 0.000058 (accessed April 2016).
Mutations at Residues R124 and R555 Demonstrate
Complete Genotype–Phenotype Correlation
The most common mutations in our corneal dystrophy cohort
occurred at the two mutation hot-spot residues, R124 and
R555 (Fig. 1A, Table). Six distinct mutations affecting these
residues have been described, each of which correlates with a
well-characterized clinical phenotype.1,2 In our cohort, we
identified five of these mutations; however, the reported
GCD1-associated mutation p.(R124S) was absent (Figs. 1A,
1B).1–3
Thiel-Behnke and Reis-Bu¨cklers Corneal
Dystrophy
The c.1664G>A; p.(R555Q) mutation, reported to be associ-
ated with TBCD, was identified in 20 unrelated probands,
whereas the RBCD-associated mutation (c.371G>T; p.[R124L])
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was found in only one patient, demonstrating that TBCD is
more prevalent in our patient population (Fig. 1A). All
individuals in this group had anterior stromal opacity as
previously described (Fig. 1B).
Granular Corneal Dystrophy
Consistent with previous reports, individuals with GCD1 had
predominantly deep granular opacities, while individuals with
GCD2 had predominantly anterior stromal snowflake opacities
(Fig. 1B). The GCD1 mutation c.1663C>T; p.(R555W) was
more commonly detected (13 probands) than the GCD2
mutation c.371G>A; p.(R124H) (8 probands, Fig. 1A, Table).
Lattice Corneal Dystrophy
Twenty-four probands had a phenotype consistent with LCD.
The most common mutation was p.(R124C) found in 19
individuals (Fig. 1A, Table). All individuals carrying this
mutation had branching refractile lines and stromal haze
consistent with the classic lattice phenotype (Fig. 1B).
Lattice Corneal Dystrophy Caused by Mutations in
TGFBI Exon 14
Two probands (F18 and F84) had the mutation c.1877A>G;
p.(H626R) (Fig. 2). In family F18, the proband’s brother had
asymmetric progression of disease with only minor changes in
FIGURE 1. Genotype–phenotype correlation for mutations affecting mutation hot-spot residues R124 and R555. (A) Graph shows the clinical
diagnosis and genotype of 61 probands harboring a TGFBI mutation affecting either amino acid R124 or R555. There is complete correlation
between genotype and phenotype. (B) Where available, representative clinical images of the phenotype associated with mutations affecting R124
and R555 are shown.
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one eye (Fig. 2C), consistent with previous reports of
asymmetric disease associated with this mutation.6,16–18 The
clinical phenotype in both individuals was mild, with lattice
lines predominantly below the visual axis.
Proband F14 was of South Asian ethnicity and was initially
diagnosed with RBCD. TGFBI sequencing identified a hetero-
zygous c.1874T>A; p.(V625D) mutation (Fig. 3B). The
proband had a diffuse anterior stromal haze combined with
small granular focal opacities. Lattice structures could not be
visualized on biomicroscopy (Fig. 3C). Light microscopy
demonstrated linear subepithelial deposition of amyloid as
well as a few fusiform deposits within the superficial stroma.
Masson’s trichrome staining was negative, and the subepithe-
lial fibrous sheet typical of RBCD and TBCD was absent,
excluding both these diagnoses. The histologic diagnosis of
lattice dystrophy was made (Fig. 3D).
Proband F60, of East Asian origin, had the c.1859C>A;
p.(A620D) mutation. The clinical appearance was consistent
with classic lattice dystrophy.
Phenotypes Associated With the TGFBI Mutation
p.(G623D)
Five probands were identified with the c.1868 G>A;
p.(G623D) mutation, also located in exon 14 (Table). The
clinical phenotype consisted of a diffuse or geographic pattern
of superficial stromal opacity, with small refractile granules or
lines. The phenotype was possibly modified by superficial
corneal scar formation secondary to multiple epithelial
erosions in both examined individuals from F70. All probands
had a relatively late disease onset (fourth decade onward), with
severe symptoms of recurrent corneal epithelial erosions and a
FIGURE 2. TGFBI mutation p.(H626R) identified in two families with LCD. (A) Pedigree showing inheritance of LCD in two unrelated families. The
proband of the family is highlighted with an arrow. DNA samples were obtained from individuals indicated with a * (B) Sequence electropherogram
shows the presence of a heterozygous c.1877A>G; p.(H626R) mutation in exon 14. (C) Slit-lamp image shows minor lattice lines in one eye of IV:2
(F18).
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delay before a diagnosis of corneal dystrophy was considered.
There had been diagnostic uncertainty in this cohort, with a
diagnosis of LCD in one proband (F51), RBCD/TBCD in two
probands (F21, F46), and EBMD in two probands (F59 and
F70).
Proband F51 had late onset of severe recurrent corneal
epithelial erosion in his sixties. There was a diffuse axial
anterior stromal haze with small lattice structures resulting in a
clinical diagnosis of LCD. The symptoms from erosion settled
following laser phototherapeutic keratectomy (PTK) (Fig. 4A).
Proband F21 had been managed for several years for
presumed bilateral herpes simplex keratitis before a diagnosis
of RBCD/TBCD was considered. There was a geographic
pattern of subepithelial haze and tiny granular structures (Fig.
4B). Her symptoms greatly reduced following laser PTK.
Similarly, F46 had a diffuse subepithelial haze and small
refractile structures (Fig. 4C). She had initially been managed
for EBMD before a diagnosis of RBCD was considered.
Proband F59 had elevated serpiginous superficial opacities
of both corneas, possibly secondary to subepithelial scar
formation, but without stromal granular or lattice structures
(Fig. 4F). His father was not clinically examined but had been
previously diagnosed with dry eye disease. Proband F70 and
his father both had a similar pattern of focal superficial stromal
opacities without stromal deposits (Figs. 4D, 4E). Again, it was
uncertain whether these changes were owing to primary
disease or scarring from recurrent episodes of epithelial
breakdown.
The remaining 21 probands diagnosed with EBMD were
negative for potentially pathogenic changes in all TGFBI
protein coding exons and negative for the two ERED-associated
mutations (p.[Thr939Ile] and p.[Gly1052Gly]) in COL17A1.
DISCUSSION
Over 60 pathogenic TGFBI mutations have been described to
date. However, in our large multi-ethnic cohort, we found only
a limited spectrum of nine mutations responsible for TGFBI-
associated disease (Table). The p.(R555Q), p.(R555W), and
p.(R124C) mutations, causing TBCD, GCD1, and LCD, respec-
tively, were the most common, which is consistent with a
previous case series of 16 probands.19 Of interest, in the great
FIGURE 3. Inheritance of TGFBI p.(V625D) mutation associated with atypical LCD in proband F14. (A) Pedigree indicates an autosomal dominant
inheritance of corneal dystrophy. (B) Sequencing TGFBI revealed the presence of a heterozygous c.1874T>A; p.(V625D) mutation in exon 14. (C)
Slit-lamp image shows diffuse anterior stromal haze combined with small granular focal opacities. (D) Histologic sample demonstrates amyloid
predominantly located near Bowman’s layer (arrow) with a few stromal deposits (doubled-headed arrow), resulting in a diagnosis of LCD.
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majority of individuals with anterior stromal dystrophy we
identified the p.(R555Q) mutation that has been associated
with TBCD, with only a single proband carrying the p.(R124L)
RBCD-associated mutation.
There were three mutations in this cohort that caused LCD
in addition to the common hot-spot change for this condition.
The p.(H626R) change, that we identified in two probands, is
the most common LCD-associated mutation in Mexican20 and
Vietnamese16 populations. The reported phenotype is de-
scribed as atypical, with fewer, thicker lattice lines and a late
onset compared with classic LCD.16 This was consistent with
the mild disease observed in family F18. The c.1874T>A;
p.(V625D) mutation has been previously reported in one
Chinese family with LCD; however, in this family, lattice lines
were observed in the proband but not in his affected mother.21
Histology confirmed the diagnosis of LCD in our proband with
this mutation. The c.1859C>A; p.(A620D) mutation, identified
in our proband of South Asian ethnicity, has also been
previously reported in a Chinese patient.22
When we included the EBMD cohort, five unrelated
probands harbored the p.(G623D) mutation. This mutation is
therefore more prevalent in the United Kingdom population
than previously recognized, and it accounts for a substantial
proportion of the disease burden. The p.(G623D) mutation has
been identified in patients from Filipino, European, and
Chinese populations; therefore, it likely represents a mutation
hot spot rather than an inherited founder mutation.3,23–26
Although the genotype–phenotype correlation for most
TGFBI mutations is generally consistent, individuals with the
p.(G623D) mutation had a range of clinical signs leading to
clinical diagnoses of RBCD/TBCD, LCD, or EBMD and, in some
cases, had been previously misdiagnosed with bilateral herpes
simplex keratitis or dry eye disease. It is probable that studies
that do not consider a diagnosis of epithelial-stromal TGFBI
dystrophy in patients with EBMD or other chronic ocular
surface diseases will underestimate the prevalence of this
mutation. Six other families carrying the p.(G623D) mutation
have been described previously.3,23–26 The most common
phenotype is a geographic pattern of opacities at Bowman’s
layer, consistent with RBCD,23 although some individuals also
have the stromal lattice lines of LCD.26 The majority of families
described have similar clinical features within the affected
family,27 although some have intrafamilial variation.24 The
phenotypic variability associated with p.(G623D) may be the
result of environmental or genetic modifiers of this mutation,
secondary corneal scarring (Salzmann degeneration), or the
accumulation of amyloid with age to form lattice lines in older
individuals.
The histology of corneal tissue from individuals with the
p.(G623D) mutation is also variable. One patient with clinical
features of RBCD had opacities that were negative for PAS,
Masson’s trichrome, and Congo Red.23 In another family with
the p.(G623D) mutation, five corneal buttons were analyzed
from three affected siblings with superficial opacities similar to
Salzmann’s nodular degeneration. These were positive for
amyloid in Bowman’s layer and the stroma.24 Three other
probands with map-like opacities and lattice lines also had
tissue that stained positive for amyloid.25
The different pathogenic mutations located in the fourth
fasciclin-1 (FAS-1) domain of the protein (Fig. 5), result in
FIGURE 4. Phenotypic spectrum of disease associated with the p.(G623D) mutation. Clinical phenotype in five probands with the p.(G623D)
mutation ranged from lattice lines in F51 (arrows) (A), opacities located at Bowman’s layer in F21 (B) and F46 (C), and changes of the epithelial
basement membrane in F70 (D, son of the proband F70; E, proband F70) and F59 (F).
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specific physiochemical differences in the TGFBI protein,
which may provide an insight into the diverse clinical
phenotypes observed. The p.(R555W) mutant protein, associ-
ated with a GCD1 phenotype, has increased thermodynamic
stability and is more resistant to proteolytic digestion than the
wild-type protein. Conversely, the p.(A546T) protein (associ-
ated with LCD) has reduced stability and is more prone to
proteolytic digestion relative to the wild-type protein.28,29 The
reduction of thermodynamic stability exposes a ‘‘fibril-core’’
(Y571-R588), which is released by proteolytic cleavage. Once
released, these peptides form amyloid fibrils, which subse-
quently aggregate.30 Given the clinical and histologic variability
associated with the p.(G623D) mutation, it would be inter-
esting to further investigate the mutant protein to determine
its thermodynamic stability and aggregation propensity.
A previous study that screened TGFBI in a cohort of EBMD
patients estimated that approximately 10% of these individuals
have mutations in TGFBI.10 This is consistent with our finding
that p.(G623D) was present in 9% of the EBMD cohort;
although neither of the two previously reported TGFBI
mutations (p.[L509R] and p.[R666S]) were observed. Genetic
testing is rarely performed for individuals with EBMD, as the
basis for disease is thought to be degenerative. However, our
results demonstrate that a reevaluation of a diagnosis of EBMD
is warranted in some patients, particularly where there is a
family history of corneal disease, when screening for TGFBI
may be informative.
Identification of the p.(G623D) mutation in the EBMD
cohort has important implications for clinical management and
counseling for patients and their families, especially consider-
ing that in patients carrying this mutation, the symptoms of
painful epithelial erosion improved markedly following PTK.
There are also implications for patients with TGFBI dystrophies
if they undergo LASIK.31 Following photorefractive keratecto-
my (PRK) and LASIK surgery, an increase in stromal deposits
and loss of visual acuity has been reported in several GCD2
patients carrying the TGFBI p.(R124H) mutation. Histology
showed increased TGFBI hyaline deposits, particularly at the
margin of the LASIK flap and in the stromal interface.32–34 This
may be owing to an upregulation of TGF-b1 expression by
stromal fibroblasts after injury, which is part of the normal
corneal wound healing response.35
The etiology of disease in the remaining EBMD patients in
our cohort, including two probands with a family history of
corneal erosions, who were negative for a mutation in TGFBI
and for the two reported COL17A1 mutations, is unknown.
The relative contribution of alternative mutations in COL17A1,
mutations in other as yet undiscovered gene(s), or corneal
degeneration in this patient group remains to be elucidated.
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